Literature DB >> 33048349

Aetiology and pathogenesis of hidradenitis suppurativa.

K Wolk1, O Join-Lambert2,3, R Sabat4,5.   

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory disorder. Patients develop inflamed nodules and abscesses and, at later stages of disease, epithelialized tunnels and scars in skinfolds of axillary, inguinal, gluteal and perianal areas. Quality of life is affected due to severe pain, purulent secretion, restricted mobility and systemic involvement. Genetics and lifestyle factors including smoking and obesity contribute to the development of HS. These factors lead to microbiome alteration, subclinical inflammation around the terminal hair follicles, and infundibular hyperkeratosis, resulting in plugging and rupture of the follicles. Cell-damage-associated molecules and propagating bacteria trigger inflammation and lead to massive immune cell infiltration that clinically manifests as inflamed nodules and abscesses. The immune system plays a key role also in the progression and chronification of skin alterations. Innate proinflammatory cytokines (e.g. interleukin-1β and tumour necrosis factor-α), mediators of activated T helper (Th)1 and Th17 cells (e.g. interleukin-17 and interferon-γ), and effector mechanisms of neutrophilic granulocytes, macrophages and plasma cells are involved. Simultaneously, skin lesions contain anti-inflammatory mediators (e.g. interleukin-10) and show limited activity of Th22 and regulatory T cells. The inflammatory vicious circle finally results in pain, purulence, tissue destruction and scarring. Chronic inflammation in patients with HS is also frequently detected in organs other than the skin, as indicated by their comorbidities. All these aspects represent a challenge for the development of therapeutic approaches, which are urgently needed for this debilitating disease. This scholarly review focuses on the causes and pathogenetic mechanisms of HS and the potential therapeutic value of this knowledge.
© 2020 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Entities:  

Mesh:

Year:  2020        PMID: 33048349     DOI: 10.1111/bjd.19556

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  13 in total

Review 1.  Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.

Authors:  Hideyuki Ujiie; David Rosmarin; Michael P Schön; Sonja Ständer; Katharina Boch; Martin Metz; Marcus Maurer; Diamant Thaci; Enno Schmidt; Connor Cole; Kyle T Amber; Dario Didona; Michael Hertl; Andreas Recke; Hanna Graßhoff; Alexander Hackel; Anja Schumann; Gabriela Riemekasten; Katja Bieber; Gant Sprow; Joshua Dan; Detlef Zillikens; Tanya Sezin; Angela M Christiano; Kerstin Wolk; Robert Sabat; Khalaf Kridin; Victoria P Werth; Ralf J Ludwig
Journal:  Front Med (Lausanne)       Date:  2022-06-09

2.  Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.

Authors:  Kristina Navrazhina; John W Frew; David Grand; Samuel C Williams; Hong Hur; Juana Gonzalez; Sandra Garcet; James G Krueger
Journal:  Br J Dermatol       Date:  2022-06-02       Impact factor: 11.113

Review 3.  [Pathogenesis of hidradenitis suppurativa/acne inversa].

Authors:  G Nikolakis; G Kokolakis; K Kaleta; K Wolk; R Hunger; R Sabat; C C Zouboulis
Journal:  Hautarzt       Date:  2021-07-06       Impact factor: 0.751

4.  Features Associated With Quality of Life Impairment in Hidradenitis Suppurativa Patients.

Authors:  Sylke Schneider-Burrus; Athanasia Tsaousi; Sebastian Barbus; Johannes Huss-Marp; Katrin Witte; Kerstin Wolk; Björn Fritz; Robert Sabat
Journal:  Front Med (Lausanne)       Date:  2021-04-27

5.  Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa.

Authors:  Ester Del Duca; Paola Morelli; Luigi Bennardo; Cosimo Di Raimondo; Steven Paul Nisticò
Journal:  Int J Mol Sci       Date:  2020-11-10       Impact factor: 5.923

6.  Characterization of comorbidity heterogeneity among 13,667 patients with hidradenitis suppurativa.

Authors:  Vivian J Hua; James M Kilgour; Hyunje G Cho; Shufeng Li; Kavita Y Sarin
Journal:  JCI Insight       Date:  2021-11-08

7.  Mediterranean diet, lifestyle and quality of life in Sardinian patients affected with Hidradenitis suppurativa.

Authors:  Fernanda Velluzzi; Jasmine Anedda; Silvia Pisanu; Massimo Dell'Antonia; Andrea Deledda; Alessandro Boi; Caterina Ferreli; Laura Atzori
Journal:  J Public Health Res       Date:  2021-11-29

Review 8.  Aquaporins Are One of the Critical Factors in the Disruption of the Skin Barrier in Inflammatory Skin Diseases.

Authors:  Paola Maura Tricarico; Donatella Mentino; Aurora De Marco; Cecilia Del Vecchio; Sabino Garra; Gerardo Cazzato; Caterina Foti; Sergio Crovella; Giuseppe Calamita
Journal:  Int J Mol Sci       Date:  2022-04-05       Impact factor: 5.923

9.  Hidradenitis suppurativa among patients with HIV: investigating patient and disease characteristics and misdiagnosis.

Authors:  H Bui; P N Skiba; A Breskin; C Sayed
Journal:  Br J Dermatol       Date:  2021-08-17       Impact factor: 9.302

10.  Association of Trimethylamine N-Oxide (TMAO) with the Clinical Severity of Hidradenitis Suppurativa (Acne Inversa).

Authors:  Luigi Barrea; Giovanna Muscogiuri; Gabriella Pugliese; Giulia de Alteriis; Maria Maisto; Marianna Donnarumma; Gian Carlo Tenore; Annamaria Colao; Gabriella Fabbrocini; Silvia Savastano
Journal:  Nutrients       Date:  2021-06-10       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.